nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanfacine—Phenacemide—Vorinostat—hematologic cancer	0.386	1	CrCrCtD
Guanfacine—CYP2C9—Bexarotene—hematologic cancer	0.0243	0.0628	CbGbCtD
Guanfacine—CYP2C9—Idarubicin—hematologic cancer	0.0202	0.0521	CbGbCtD
Guanfacine—CYP2C19—Bortezomib—hematologic cancer	0.0179	0.0463	CbGbCtD
Guanfacine—CYP2C19—Thalidomide—hematologic cancer	0.0156	0.0404	CbGbCtD
Guanfacine—CYP2C9—Bortezomib—hematologic cancer	0.0149	0.0385	CbGbCtD
Guanfacine—CYP2C19—Teniposide—hematologic cancer	0.0149	0.0385	CbGbCtD
Guanfacine—CYP3A4—Bexarotene—hematologic cancer	0.0142	0.0365	CbGbCtD
Guanfacine—CYP2C19—Ifosfamide—hematologic cancer	0.0138	0.0355	CbGbCtD
Guanfacine—CYP3A4—Busulfan—hematologic cancer	0.0132	0.034	CbGbCtD
Guanfacine—CYP3A4—Lomustine—hematologic cancer	0.0132	0.034	CbGbCtD
Guanfacine—CYP2C19—Imatinib—hematologic cancer	0.0131	0.0339	CbGbCtD
Guanfacine—CYP2C9—Thalidomide—hematologic cancer	0.013	0.0335	CbGbCtD
Guanfacine—CYP2C9—Teniposide—hematologic cancer	0.0124	0.032	CbGbCtD
Guanfacine—CYP3A4—Thiotepa—hematologic cancer	0.0117	0.0303	CbGbCtD
Guanfacine—CYP2C9—Ifosfamide—hematologic cancer	0.0114	0.0295	CbGbCtD
Guanfacine—CYP2C9—Imatinib—hematologic cancer	0.0109	0.0282	CbGbCtD
Guanfacine—CYP2C9—Nilotinib—hematologic cancer	0.00993	0.0256	CbGbCtD
Guanfacine—CYP3A4—Methoxsalen—hematologic cancer	0.00912	0.0235	CbGbCtD
Guanfacine—CYP3A4—Bortezomib—hematologic cancer	0.00867	0.0224	CbGbCtD
Guanfacine—CYP2C19—Prednisone—hematologic cancer	0.00866	0.0224	CbGbCtD
Guanfacine—CYP3A4—Daunorubicin—hematologic cancer	0.0083	0.0214	CbGbCtD
Guanfacine—CYP3A4—Cytarabine—hematologic cancer	0.00732	0.0189	CbGbCtD
Guanfacine—CYP3A4—Teniposide—hematologic cancer	0.00721	0.0186	CbGbCtD
Guanfacine—CYP3A4—Ifosfamide—hematologic cancer	0.00665	0.0172	CbGbCtD
Guanfacine—CYP3A4—Imatinib—hematologic cancer	0.00635	0.0164	CbGbCtD
Guanfacine—CYP3A4—Ruxolitinib—hematologic cancer	0.00598	0.0154	CbGbCtD
Guanfacine—CYP3A4—Nilotinib—hematologic cancer	0.00577	0.0149	CbGbCtD
Guanfacine—CYP3A4—Vinorelbine—hematologic cancer	0.00573	0.0148	CbGbCtD
Guanfacine—CYP2C9—Cisplatin—hematologic cancer	0.00556	0.0144	CbGbCtD
Guanfacine—CYP2C19—Dexamethasone—hematologic cancer	0.00541	0.014	CbGbCtD
Guanfacine—CYP3A4—Triamcinolone—hematologic cancer	0.00524	0.0135	CbGbCtD
Guanfacine—CYP3A4—Dasatinib—hematologic cancer	0.0051	0.0132	CbGbCtD
Guanfacine—CYP3A4—Mitoxantrone—hematologic cancer	0.00504	0.013	CbGbCtD
Guanfacine—CYP2C9—Dexamethasone—hematologic cancer	0.0045	0.0116	CbGbCtD
Guanfacine—CYP3A4—Betamethasone—hematologic cancer	0.00449	0.0116	CbGbCtD
Guanfacine—CYP3A4—Prednisolone—hematologic cancer	0.00443	0.0114	CbGbCtD
Guanfacine—CYP3A4—Prednisone—hematologic cancer	0.00419	0.0108	CbGbCtD
Guanfacine—CYP3A4—Irinotecan—hematologic cancer	0.00397	0.0102	CbGbCtD
Guanfacine—CYP3A4—Vinblastine—hematologic cancer	0.00353	0.00911	CbGbCtD
Guanfacine—CYP3A4—Vincristine—hematologic cancer	0.00347	0.00896	CbGbCtD
Guanfacine—CYP3A4—Etoposide—hematologic cancer	0.00318	0.00821	CbGbCtD
Guanfacine—CYP3A4—Dexamethasone—hematologic cancer	0.00261	0.00675	CbGbCtD
Guanfacine—CYP3A4—Doxorubicin—hematologic cancer	0.00217	0.0056	CbGbCtD
Guanfacine—NISCH—Podofilox—Teniposide—hematologic cancer	0.000816	0.226	CbGdCrCtD
Guanfacine—NISCH—Menadione—Thalidomide—hematologic cancer	0.000619	0.172	CbGdCrCtD
Guanfacine—Diclofenac—ALOX5—hematologic cancer	0.000617	0.435	CrCbGaD
Guanfacine—Diclofenac—UGT1A1—hematologic cancer	0.000542	0.382	CrCbGaD
Guanfacine—NISCH—Vincristine—Vinorelbine—hematologic cancer	0.00052	0.144	CbGdCrCtD
Guanfacine—NISCH—Podofilox—Etoposide—hematologic cancer	0.000485	0.135	CbGdCrCtD
Guanfacine—NISCH—Vinblastine—Vinorelbine—hematologic cancer	0.000418	0.116	CbGdCrCtD
Guanfacine—NISCH—Vincristine—Vinblastine—hematologic cancer	0.000415	0.115	CbGdCrCtD
Guanfacine—NISCH—Vinblastine—Vincristine—hematologic cancer	0.000334	0.0926	CbGdCrCtD
Guanfacine—NISCH—blood—hematologic cancer	0.000263	0.107	CbGeAlD
Guanfacine—NISCH—bone marrow—hematologic cancer	0.000254	0.104	CbGeAlD
Guanfacine—NISCH—lung—hematologic cancer	0.00023	0.094	CbGeAlD
Guanfacine—NISCH—testis—hematologic cancer	0.000217	0.0887	CbGeAlD
Guanfacine—CYP2C19—hematopoietic system—hematologic cancer	0.000193	0.0785	CbGeAlD
Guanfacine—NISCH—lymph node—hematologic cancer	0.000158	0.0643	CbGeAlD
Guanfacine—CYP2C9—hematopoietic system—hematologic cancer	0.000149	0.0609	CbGeAlD
Guanfacine—ADRA2A—hematopoietic system—hematologic cancer	0.000145	0.059	CbGeAlD
Guanfacine—Diclofenac—ALB—hematologic cancer	0.000133	0.0936	CrCbGaD
Guanfacine—CYP2C19—blood—hematologic cancer	0.000128	0.052	CbGeAlD
Guanfacine—Diclofenac—ABCB1—hematologic cancer	0.000127	0.0894	CrCbGaD
Guanfacine—CYP3A4—hematopoietic system—hematologic cancer	0.000114	0.0464	CbGeAlD
Guanfacine—ADRA2A—gonad—hematologic cancer	0.00011	0.0449	CbGeAlD
Guanfacine—CYP2C9—blood—hematologic cancer	9.89e-05	0.0403	CbGeAlD
Guanfacine—ADRA2A—blood—hematologic cancer	9.58e-05	0.0391	CbGeAlD
Guanfacine—ADRA2A—lung—hematologic cancer	8.4e-05	0.0343	CbGeAlD
Guanfacine—ADRA2A—testis—hematologic cancer	7.93e-05	0.0323	CbGeAlD
Guanfacine—CYP3A4—blood—hematologic cancer	7.54e-05	0.0308	CbGeAlD
Guanfacine—ADRA2A—lymph node—hematologic cancer	5.74e-05	0.0234	CbGeAlD
Guanfacine—Dermatitis—Mitoxantrone—hematologic cancer	3.64e-05	0.000189	CcSEcCtD
Guanfacine—Dermatitis—Irinotecan—hematologic cancer	3.64e-05	0.000189	CcSEcCtD
Guanfacine—Headache—Irinotecan—hematologic cancer	3.62e-05	0.000188	CcSEcCtD
Guanfacine—Headache—Mitoxantrone—hematologic cancer	3.62e-05	0.000188	CcSEcCtD
Guanfacine—Nausea—Ifosfamide—hematologic cancer	3.61e-05	0.000187	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	3.6e-05	0.000187	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	3.6e-05	0.000187	CcSEcCtD
Guanfacine—Myalgia—Prednisone—hematologic cancer	3.59e-05	0.000186	CcSEcCtD
Guanfacine—Arthralgia—Prednisone—hematologic cancer	3.59e-05	0.000186	CcSEcCtD
Guanfacine—Feeling abnormal—Triamcinolone—hematologic cancer	3.59e-05	0.000186	CcSEcCtD
Guanfacine—Diarrhoea—Cisplatin—hematologic cancer	3.59e-05	0.000186	CcSEcCtD
Guanfacine—Anxiety—Prednisone—hematologic cancer	3.58e-05	0.000186	CcSEcCtD
Guanfacine—Alopecia—Methotrexate—hematologic cancer	3.58e-05	0.000186	CcSEcCtD
Guanfacine—Vomiting—Gemcitabine—hematologic cancer	3.58e-05	0.000186	CcSEcCtD
Guanfacine—Insomnia—Dexamethasone—hematologic cancer	3.58e-05	0.000185	CcSEcCtD
Guanfacine—Insomnia—Betamethasone—hematologic cancer	3.58e-05	0.000185	CcSEcCtD
Guanfacine—Bradycardia—Doxorubicin—hematologic cancer	3.57e-05	0.000185	CcSEcCtD
Guanfacine—Paraesthesia—Dexamethasone—hematologic cancer	3.55e-05	0.000184	CcSEcCtD
Guanfacine—Paraesthesia—Betamethasone—hematologic cancer	3.55e-05	0.000184	CcSEcCtD
Guanfacine—Discomfort—Prednisone—hematologic cancer	3.55e-05	0.000184	CcSEcCtD
Guanfacine—Rash—Gemcitabine—hematologic cancer	3.55e-05	0.000184	CcSEcCtD
Guanfacine—Dermatitis—Gemcitabine—hematologic cancer	3.54e-05	0.000184	CcSEcCtD
Guanfacine—Eye disorder—Epirubicin—hematologic cancer	3.54e-05	0.000184	CcSEcCtD
Guanfacine—Hypersensitivity—Etoposide—hematologic cancer	3.54e-05	0.000184	CcSEcCtD
Guanfacine—Tinnitus—Epirubicin—hematologic cancer	3.53e-05	0.000183	CcSEcCtD
Guanfacine—Headache—Gemcitabine—hematologic cancer	3.52e-05	0.000183	CcSEcCtD
Guanfacine—Nausea—Vincristine—hematologic cancer	3.52e-05	0.000183	CcSEcCtD
Guanfacine—Rhinitis—Doxorubicin—hematologic cancer	3.52e-05	0.000182	CcSEcCtD
Guanfacine—Hypersensitivity—Prednisolone—hematologic cancer	3.49e-05	0.000181	CcSEcCtD
Guanfacine—Dyspepsia—Dexamethasone—hematologic cancer	3.48e-05	0.000181	CcSEcCtD
Guanfacine—Dyspepsia—Betamethasone—hematologic cancer	3.48e-05	0.000181	CcSEcCtD
Guanfacine—Dysgeusia—Methotrexate—hematologic cancer	3.45e-05	0.000179	CcSEcCtD
Guanfacine—Asthenia—Etoposide—hematologic cancer	3.45e-05	0.000179	CcSEcCtD
Guanfacine—Oedema—Prednisone—hematologic cancer	3.44e-05	0.000179	CcSEcCtD
Guanfacine—Decreased appetite—Betamethasone—hematologic cancer	3.44e-05	0.000178	CcSEcCtD
Guanfacine—Decreased appetite—Dexamethasone—hematologic cancer	3.44e-05	0.000178	CcSEcCtD
Guanfacine—Nausea—Irinotecan—hematologic cancer	3.43e-05	0.000178	CcSEcCtD
Guanfacine—Nausea—Mitoxantrone—hematologic cancer	3.43e-05	0.000178	CcSEcCtD
Guanfacine—Immune system disorder—Epirubicin—hematologic cancer	3.42e-05	0.000178	CcSEcCtD
Guanfacine—Fatigue—Betamethasone—hematologic cancer	3.41e-05	0.000177	CcSEcCtD
Guanfacine—Fatigue—Dexamethasone—hematologic cancer	3.41e-05	0.000177	CcSEcCtD
Guanfacine—Pruritus—Etoposide—hematologic cancer	3.4e-05	0.000176	CcSEcCtD
Guanfacine—Shock—Prednisone—hematologic cancer	3.39e-05	0.000176	CcSEcCtD
Guanfacine—Visual impairment—Doxorubicin—hematologic cancer	3.38e-05	0.000175	CcSEcCtD
Guanfacine—Tachycardia—Prednisone—hematologic cancer	3.36e-05	0.000174	CcSEcCtD
Guanfacine—Alopecia—Epirubicin—hematologic cancer	3.35e-05	0.000174	CcSEcCtD
Guanfacine—Nausea—Gemcitabine—hematologic cancer	3.34e-05	0.000173	CcSEcCtD
Guanfacine—Vomiting—Cisplatin—hematologic cancer	3.33e-05	0.000173	CcSEcCtD
Guanfacine—Hyperhidrosis—Prednisone—hematologic cancer	3.33e-05	0.000173	CcSEcCtD
Guanfacine—Vision blurred—Methotrexate—hematologic cancer	3.32e-05	0.000172	CcSEcCtD
Guanfacine—Rash—Cisplatin—hematologic cancer	3.31e-05	0.000172	CcSEcCtD
Guanfacine—Dermatitis—Cisplatin—hematologic cancer	3.3e-05	0.000171	CcSEcCtD
Guanfacine—Diarrhoea—Etoposide—hematologic cancer	3.29e-05	0.00017	CcSEcCtD
Guanfacine—Eye disorder—Doxorubicin—hematologic cancer	3.28e-05	0.00017	CcSEcCtD
Guanfacine—Ill-defined disorder—Methotrexate—hematologic cancer	3.27e-05	0.00017	CcSEcCtD
Guanfacine—Tinnitus—Doxorubicin—hematologic cancer	3.27e-05	0.00017	CcSEcCtD
Guanfacine—Feeling abnormal—Dexamethasone—hematologic cancer	3.26e-05	0.000169	CcSEcCtD
Guanfacine—Feeling abnormal—Betamethasone—hematologic cancer	3.26e-05	0.000169	CcSEcCtD
Guanfacine—Tension—Epirubicin—hematologic cancer	3.24e-05	0.000168	CcSEcCtD
Guanfacine—Gastrointestinal pain—Betamethasone—hematologic cancer	3.23e-05	0.000168	CcSEcCtD
Guanfacine—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.23e-05	0.000168	CcSEcCtD
Guanfacine—Dysgeusia—Epirubicin—hematologic cancer	3.23e-05	0.000168	CcSEcCtD
Guanfacine—Hypersensitivity—Triamcinolone—hematologic cancer	3.21e-05	0.000167	CcSEcCtD
Guanfacine—Nervousness—Epirubicin—hematologic cancer	3.2e-05	0.000166	CcSEcCtD
Guanfacine—Malaise—Methotrexate—hematologic cancer	3.18e-05	0.000165	CcSEcCtD
Guanfacine—Dizziness—Etoposide—hematologic cancer	3.18e-05	0.000165	CcSEcCtD
Guanfacine—Muscle spasms—Epirubicin—hematologic cancer	3.17e-05	0.000165	CcSEcCtD
Guanfacine—Immune system disorder—Doxorubicin—hematologic cancer	3.17e-05	0.000164	CcSEcCtD
Guanfacine—Vertigo—Methotrexate—hematologic cancer	3.17e-05	0.000164	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.14e-05	0.000163	CcSEcCtD
Guanfacine—Dizziness—Prednisolone—hematologic cancer	3.13e-05	0.000163	CcSEcCtD
Guanfacine—Asthenia—Triamcinolone—hematologic cancer	3.13e-05	0.000162	CcSEcCtD
Guanfacine—Abdominal pain—Betamethasone—hematologic cancer	3.13e-05	0.000162	CcSEcCtD
Guanfacine—Abdominal pain—Dexamethasone—hematologic cancer	3.13e-05	0.000162	CcSEcCtD
Guanfacine—Nausea—Cisplatin—hematologic cancer	3.11e-05	0.000162	CcSEcCtD
Guanfacine—Insomnia—Prednisone—hematologic cancer	3.11e-05	0.000162	CcSEcCtD
Guanfacine—Vision blurred—Epirubicin—hematologic cancer	3.11e-05	0.000161	CcSEcCtD
Guanfacine—Alopecia—Doxorubicin—hematologic cancer	3.1e-05	0.000161	CcSEcCtD
Guanfacine—Paraesthesia—Prednisone—hematologic cancer	3.09e-05	0.00016	CcSEcCtD
Guanfacine—Pruritus—Triamcinolone—hematologic cancer	3.08e-05	0.00016	CcSEcCtD
Guanfacine—Ill-defined disorder—Epirubicin—hematologic cancer	3.06e-05	0.000159	CcSEcCtD
Guanfacine—Convulsion—Methotrexate—hematologic cancer	3.05e-05	0.000158	CcSEcCtD
Guanfacine—Vomiting—Etoposide—hematologic cancer	3.05e-05	0.000158	CcSEcCtD
Guanfacine—Agitation—Epirubicin—hematologic cancer	3.03e-05	0.000157	CcSEcCtD
Guanfacine—Dyspepsia—Prednisone—hematologic cancer	3.03e-05	0.000157	CcSEcCtD
Guanfacine—Rash—Etoposide—hematologic cancer	3.03e-05	0.000157	CcSEcCtD
Guanfacine—Dermatitis—Etoposide—hematologic cancer	3.03e-05	0.000157	CcSEcCtD
Guanfacine—Headache—Etoposide—hematologic cancer	3.01e-05	0.000156	CcSEcCtD
Guanfacine—Arthralgia—Methotrexate—hematologic cancer	3e-05	0.000156	CcSEcCtD
Guanfacine—Chest pain—Methotrexate—hematologic cancer	3e-05	0.000156	CcSEcCtD
Guanfacine—Myalgia—Methotrexate—hematologic cancer	3e-05	0.000156	CcSEcCtD
Guanfacine—Tension—Doxorubicin—hematologic cancer	3e-05	0.000155	CcSEcCtD
Guanfacine—Decreased appetite—Prednisone—hematologic cancer	2.99e-05	0.000155	CcSEcCtD
Guanfacine—Dysgeusia—Doxorubicin—hematologic cancer	2.99e-05	0.000155	CcSEcCtD
Guanfacine—Rash—Prednisolone—hematologic cancer	2.99e-05	0.000155	CcSEcCtD
Guanfacine—Dermatitis—Prednisolone—hematologic cancer	2.98e-05	0.000155	CcSEcCtD
Guanfacine—Malaise—Epirubicin—hematologic cancer	2.98e-05	0.000154	CcSEcCtD
Guanfacine—Fatigue—Prednisone—hematologic cancer	2.97e-05	0.000154	CcSEcCtD
Guanfacine—Headache—Prednisolone—hematologic cancer	2.97e-05	0.000154	CcSEcCtD
Guanfacine—Discomfort—Methotrexate—hematologic cancer	2.97e-05	0.000154	CcSEcCtD
Guanfacine—Nervousness—Doxorubicin—hematologic cancer	2.97e-05	0.000154	CcSEcCtD
Guanfacine—Vertigo—Epirubicin—hematologic cancer	2.96e-05	0.000154	CcSEcCtD
Guanfacine—Syncope—Epirubicin—hematologic cancer	2.96e-05	0.000153	CcSEcCtD
Guanfacine—Constipation—Prednisone—hematologic cancer	2.94e-05	0.000153	CcSEcCtD
Guanfacine—Muscle spasms—Doxorubicin—hematologic cancer	2.94e-05	0.000152	CcSEcCtD
Guanfacine—Palpitations—Epirubicin—hematologic cancer	2.92e-05	0.000151	CcSEcCtD
Guanfacine—Confusional state—Methotrexate—hematologic cancer	2.9e-05	0.000151	CcSEcCtD
Guanfacine—Loss of consciousness—Epirubicin—hematologic cancer	2.9e-05	0.00015	CcSEcCtD
Guanfacine—Dizziness—Triamcinolone—hematologic cancer	2.88e-05	0.000149	CcSEcCtD
Guanfacine—Vision blurred—Doxorubicin—hematologic cancer	2.88e-05	0.000149	CcSEcCtD
Guanfacine—Convulsion—Epirubicin—hematologic cancer	2.86e-05	0.000148	CcSEcCtD
Guanfacine—Nausea—Etoposide—hematologic cancer	2.85e-05	0.000148	CcSEcCtD
Guanfacine—Hypertension—Epirubicin—hematologic cancer	2.85e-05	0.000148	CcSEcCtD
Guanfacine—Feeling abnormal—Prednisone—hematologic cancer	2.84e-05	0.000147	CcSEcCtD
Guanfacine—Asthenia—Dexamethasone—hematologic cancer	2.84e-05	0.000147	CcSEcCtD
Guanfacine—Asthenia—Betamethasone—hematologic cancer	2.84e-05	0.000147	CcSEcCtD
Guanfacine—Ill-defined disorder—Doxorubicin—hematologic cancer	2.83e-05	0.000147	CcSEcCtD
Guanfacine—Gastrointestinal pain—Prednisone—hematologic cancer	2.82e-05	0.000146	CcSEcCtD
Guanfacine—Nausea—Prednisolone—hematologic cancer	2.81e-05	0.000146	CcSEcCtD
Guanfacine—Chest pain—Epirubicin—hematologic cancer	2.81e-05	0.000146	CcSEcCtD
Guanfacine—Arthralgia—Epirubicin—hematologic cancer	2.81e-05	0.000146	CcSEcCtD
Guanfacine—Myalgia—Epirubicin—hematologic cancer	2.81e-05	0.000146	CcSEcCtD
Guanfacine—Agitation—Doxorubicin—hematologic cancer	2.81e-05	0.000146	CcSEcCtD
Guanfacine—Anxiety—Epirubicin—hematologic cancer	2.8e-05	0.000145	CcSEcCtD
Guanfacine—Pruritus—Dexamethasone—hematologic cancer	2.8e-05	0.000145	CcSEcCtD
Guanfacine—Pruritus—Betamethasone—hematologic cancer	2.8e-05	0.000145	CcSEcCtD
Guanfacine—Hyperhidrosis—Methotrexate—hematologic cancer	2.78e-05	0.000144	CcSEcCtD
Guanfacine—Discomfort—Epirubicin—hematologic cancer	2.78e-05	0.000144	CcSEcCtD
Guanfacine—Vomiting—Triamcinolone—hematologic cancer	2.77e-05	0.000144	CcSEcCtD
Guanfacine—Malaise—Doxorubicin—hematologic cancer	2.75e-05	0.000143	CcSEcCtD
Guanfacine—Rash—Triamcinolone—hematologic cancer	2.75e-05	0.000143	CcSEcCtD
Guanfacine—Dry mouth—Epirubicin—hematologic cancer	2.75e-05	0.000143	CcSEcCtD
Guanfacine—Dermatitis—Triamcinolone—hematologic cancer	2.74e-05	0.000142	CcSEcCtD
Guanfacine—Vertigo—Doxorubicin—hematologic cancer	2.74e-05	0.000142	CcSEcCtD
Guanfacine—Syncope—Doxorubicin—hematologic cancer	2.74e-05	0.000142	CcSEcCtD
Guanfacine—Headache—Triamcinolone—hematologic cancer	2.73e-05	0.000142	CcSEcCtD
Guanfacine—Abdominal pain—Prednisone—hematologic cancer	2.72e-05	0.000141	CcSEcCtD
Guanfacine—Confusional state—Epirubicin—hematologic cancer	2.72e-05	0.000141	CcSEcCtD
Guanfacine—Diarrhoea—Dexamethasone—hematologic cancer	2.71e-05	0.00014	CcSEcCtD
Guanfacine—Diarrhoea—Betamethasone—hematologic cancer	2.71e-05	0.00014	CcSEcCtD
Guanfacine—Palpitations—Doxorubicin—hematologic cancer	2.7e-05	0.00014	CcSEcCtD
Guanfacine—Oedema—Epirubicin—hematologic cancer	2.69e-05	0.00014	CcSEcCtD
Guanfacine—Hypotension—Methotrexate—hematologic cancer	2.69e-05	0.000139	CcSEcCtD
Guanfacine—Loss of consciousness—Doxorubicin—hematologic cancer	2.68e-05	0.000139	CcSEcCtD
Guanfacine—Shock—Epirubicin—hematologic cancer	2.65e-05	0.000137	CcSEcCtD
Guanfacine—Convulsion—Doxorubicin—hematologic cancer	2.65e-05	0.000137	CcSEcCtD
Guanfacine—Hypertension—Doxorubicin—hematologic cancer	2.64e-05	0.000137	CcSEcCtD
Guanfacine—Tachycardia—Epirubicin—hematologic cancer	2.63e-05	0.000136	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.62e-05	0.000136	CcSEcCtD
Guanfacine—Dizziness—Dexamethasone—hematologic cancer	2.61e-05	0.000136	CcSEcCtD
Guanfacine—Dizziness—Betamethasone—hematologic cancer	2.61e-05	0.000136	CcSEcCtD
Guanfacine—Hyperhidrosis—Epirubicin—hematologic cancer	2.6e-05	0.000135	CcSEcCtD
Guanfacine—Insomnia—Methotrexate—hematologic cancer	2.6e-05	0.000135	CcSEcCtD
Guanfacine—Chest pain—Doxorubicin—hematologic cancer	2.6e-05	0.000135	CcSEcCtD
Guanfacine—Arthralgia—Doxorubicin—hematologic cancer	2.6e-05	0.000135	CcSEcCtD
Guanfacine—Myalgia—Doxorubicin—hematologic cancer	2.6e-05	0.000135	CcSEcCtD
Guanfacine—Anxiety—Doxorubicin—hematologic cancer	2.59e-05	0.000134	CcSEcCtD
Guanfacine—Nausea—Triamcinolone—hematologic cancer	2.59e-05	0.000134	CcSEcCtD
Guanfacine—Paraesthesia—Methotrexate—hematologic cancer	2.58e-05	0.000134	CcSEcCtD
Guanfacine—Discomfort—Doxorubicin—hematologic cancer	2.57e-05	0.000133	CcSEcCtD
Guanfacine—Dyspnoea—Methotrexate—hematologic cancer	2.57e-05	0.000133	CcSEcCtD
Guanfacine—Somnolence—Methotrexate—hematologic cancer	2.56e-05	0.000133	CcSEcCtD
Guanfacine—Dry mouth—Doxorubicin—hematologic cancer	2.54e-05	0.000132	CcSEcCtD
Guanfacine—Hypersensitivity—Prednisone—hematologic cancer	2.54e-05	0.000132	CcSEcCtD
Guanfacine—Dyspepsia—Methotrexate—hematologic cancer	2.53e-05	0.000131	CcSEcCtD
Guanfacine—Hypotension—Epirubicin—hematologic cancer	2.52e-05	0.000131	CcSEcCtD
Guanfacine—Vomiting—Dexamethasone—hematologic cancer	2.51e-05	0.00013	CcSEcCtD
Guanfacine—Vomiting—Betamethasone—hematologic cancer	2.51e-05	0.00013	CcSEcCtD
Guanfacine—Confusional state—Doxorubicin—hematologic cancer	2.51e-05	0.00013	CcSEcCtD
Guanfacine—Decreased appetite—Methotrexate—hematologic cancer	2.5e-05	0.00013	CcSEcCtD
Guanfacine—Rash—Betamethasone—hematologic cancer	2.49e-05	0.000129	CcSEcCtD
Guanfacine—Rash—Dexamethasone—hematologic cancer	2.49e-05	0.000129	CcSEcCtD
Guanfacine—Oedema—Doxorubicin—hematologic cancer	2.49e-05	0.000129	CcSEcCtD
Guanfacine—Dermatitis—Dexamethasone—hematologic cancer	2.49e-05	0.000129	CcSEcCtD
Guanfacine—Dermatitis—Betamethasone—hematologic cancer	2.49e-05	0.000129	CcSEcCtD
Guanfacine—Fatigue—Methotrexate—hematologic cancer	2.48e-05	0.000129	CcSEcCtD
Guanfacine—Headache—Betamethasone—hematologic cancer	2.48e-05	0.000128	CcSEcCtD
Guanfacine—Headache—Dexamethasone—hematologic cancer	2.48e-05	0.000128	CcSEcCtD
Guanfacine—Asthenia—Prednisone—hematologic cancer	2.47e-05	0.000128	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.45e-05	0.000127	CcSEcCtD
Guanfacine—Shock—Doxorubicin—hematologic cancer	2.45e-05	0.000127	CcSEcCtD
Guanfacine—Pruritus—Prednisone—hematologic cancer	2.44e-05	0.000126	CcSEcCtD
Guanfacine—Insomnia—Epirubicin—hematologic cancer	2.44e-05	0.000126	CcSEcCtD
Guanfacine—Tachycardia—Doxorubicin—hematologic cancer	2.43e-05	0.000126	CcSEcCtD
Guanfacine—Paraesthesia—Epirubicin—hematologic cancer	2.42e-05	0.000125	CcSEcCtD
Guanfacine—Hyperhidrosis—Doxorubicin—hematologic cancer	2.41e-05	0.000125	CcSEcCtD
Guanfacine—Dyspnoea—Epirubicin—hematologic cancer	2.4e-05	0.000125	CcSEcCtD
Guanfacine—Somnolence—Epirubicin—hematologic cancer	2.39e-05	0.000124	CcSEcCtD
Guanfacine—Feeling abnormal—Methotrexate—hematologic cancer	2.37e-05	0.000123	CcSEcCtD
Guanfacine—Dyspepsia—Epirubicin—hematologic cancer	2.37e-05	0.000123	CcSEcCtD
Guanfacine—Diarrhoea—Prednisone—hematologic cancer	2.36e-05	0.000122	CcSEcCtD
Guanfacine—Gastrointestinal pain—Methotrexate—hematologic cancer	2.35e-05	0.000122	CcSEcCtD
Guanfacine—Nausea—Betamethasone—hematologic cancer	2.35e-05	0.000122	CcSEcCtD
Guanfacine—Nausea—Dexamethasone—hematologic cancer	2.35e-05	0.000122	CcSEcCtD
Guanfacine—Decreased appetite—Epirubicin—hematologic cancer	2.34e-05	0.000121	CcSEcCtD
Guanfacine—Hypotension—Doxorubicin—hematologic cancer	2.33e-05	0.000121	CcSEcCtD
Guanfacine—Fatigue—Epirubicin—hematologic cancer	2.32e-05	0.00012	CcSEcCtD
Guanfacine—Constipation—Epirubicin—hematologic cancer	2.3e-05	0.000119	CcSEcCtD
Guanfacine—Dizziness—Prednisone—hematologic cancer	2.28e-05	0.000118	CcSEcCtD
Guanfacine—Abdominal pain—Methotrexate—hematologic cancer	2.27e-05	0.000118	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.27e-05	0.000118	CcSEcCtD
Guanfacine—Insomnia—Doxorubicin—hematologic cancer	2.25e-05	0.000117	CcSEcCtD
Guanfacine—Paraesthesia—Doxorubicin—hematologic cancer	2.24e-05	0.000116	CcSEcCtD
Guanfacine—Dyspnoea—Doxorubicin—hematologic cancer	2.22e-05	0.000115	CcSEcCtD
Guanfacine—Feeling abnormal—Epirubicin—hematologic cancer	2.22e-05	0.000115	CcSEcCtD
Guanfacine—Somnolence—Doxorubicin—hematologic cancer	2.22e-05	0.000115	CcSEcCtD
Guanfacine—Gastrointestinal pain—Epirubicin—hematologic cancer	2.2e-05	0.000114	CcSEcCtD
Guanfacine—Dyspepsia—Doxorubicin—hematologic cancer	2.19e-05	0.000114	CcSEcCtD
Guanfacine—Vomiting—Prednisone—hematologic cancer	2.19e-05	0.000114	CcSEcCtD
Guanfacine—Rash—Prednisone—hematologic cancer	2.17e-05	0.000113	CcSEcCtD
Guanfacine—Dermatitis—Prednisone—hematologic cancer	2.17e-05	0.000113	CcSEcCtD
Guanfacine—Decreased appetite—Doxorubicin—hematologic cancer	2.17e-05	0.000112	CcSEcCtD
Guanfacine—Headache—Prednisone—hematologic cancer	2.16e-05	0.000112	CcSEcCtD
Guanfacine—Fatigue—Doxorubicin—hematologic cancer	2.15e-05	0.000111	CcSEcCtD
Guanfacine—Constipation—Doxorubicin—hematologic cancer	2.13e-05	0.000111	CcSEcCtD
Guanfacine—Abdominal pain—Epirubicin—hematologic cancer	2.13e-05	0.00011	CcSEcCtD
Guanfacine—Hypersensitivity—Methotrexate—hematologic cancer	2.12e-05	0.00011	CcSEcCtD
Guanfacine—Asthenia—Methotrexate—hematologic cancer	2.06e-05	0.000107	CcSEcCtD
Guanfacine—Feeling abnormal—Doxorubicin—hematologic cancer	2.05e-05	0.000107	CcSEcCtD
Guanfacine—Nausea—Prednisone—hematologic cancer	2.05e-05	0.000106	CcSEcCtD
Guanfacine—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.04e-05	0.000106	CcSEcCtD
Guanfacine—Pruritus—Methotrexate—hematologic cancer	2.04e-05	0.000106	CcSEcCtD
Guanfacine—Hypersensitivity—Epirubicin—hematologic cancer	1.98e-05	0.000103	CcSEcCtD
Guanfacine—Abdominal pain—Doxorubicin—hematologic cancer	1.97e-05	0.000102	CcSEcCtD
Guanfacine—Diarrhoea—Methotrexate—hematologic cancer	1.97e-05	0.000102	CcSEcCtD
Guanfacine—Asthenia—Epirubicin—hematologic cancer	1.93e-05	0.0001	CcSEcCtD
Guanfacine—Pruritus—Epirubicin—hematologic cancer	1.91e-05	9.88e-05	CcSEcCtD
Guanfacine—Dizziness—Methotrexate—hematologic cancer	1.9e-05	9.87e-05	CcSEcCtD
Guanfacine—Diarrhoea—Epirubicin—hematologic cancer	1.84e-05	9.56e-05	CcSEcCtD
Guanfacine—Hypersensitivity—Doxorubicin—hematologic cancer	1.84e-05	9.52e-05	CcSEcCtD
Guanfacine—Vomiting—Methotrexate—hematologic cancer	1.83e-05	9.49e-05	CcSEcCtD
Guanfacine—Rash—Methotrexate—hematologic cancer	1.81e-05	9.41e-05	CcSEcCtD
Guanfacine—Dermatitis—Methotrexate—hematologic cancer	1.81e-05	9.4e-05	CcSEcCtD
Guanfacine—Headache—Methotrexate—hematologic cancer	1.8e-05	9.35e-05	CcSEcCtD
Guanfacine—Asthenia—Doxorubicin—hematologic cancer	1.79e-05	9.27e-05	CcSEcCtD
Guanfacine—Dizziness—Epirubicin—hematologic cancer	1.78e-05	9.24e-05	CcSEcCtD
Guanfacine—Pruritus—Doxorubicin—hematologic cancer	1.76e-05	9.14e-05	CcSEcCtD
Guanfacine—Vomiting—Epirubicin—hematologic cancer	1.71e-05	8.88e-05	CcSEcCtD
Guanfacine—Nausea—Methotrexate—hematologic cancer	1.71e-05	8.87e-05	CcSEcCtD
Guanfacine—Diarrhoea—Doxorubicin—hematologic cancer	1.7e-05	8.84e-05	CcSEcCtD
Guanfacine—Rash—Epirubicin—hematologic cancer	1.7e-05	8.81e-05	CcSEcCtD
Guanfacine—Dermatitis—Epirubicin—hematologic cancer	1.7e-05	8.8e-05	CcSEcCtD
Guanfacine—Headache—Epirubicin—hematologic cancer	1.69e-05	8.75e-05	CcSEcCtD
Guanfacine—Dizziness—Doxorubicin—hematologic cancer	1.65e-05	8.55e-05	CcSEcCtD
Guanfacine—Nausea—Epirubicin—hematologic cancer	1.6e-05	8.3e-05	CcSEcCtD
Guanfacine—Vomiting—Doxorubicin—hematologic cancer	1.58e-05	8.22e-05	CcSEcCtD
Guanfacine—Rash—Doxorubicin—hematologic cancer	1.57e-05	8.15e-05	CcSEcCtD
Guanfacine—Dermatitis—Doxorubicin—hematologic cancer	1.57e-05	8.14e-05	CcSEcCtD
Guanfacine—Headache—Doxorubicin—hematologic cancer	1.56e-05	8.1e-05	CcSEcCtD
Guanfacine—Nausea—Doxorubicin—hematologic cancer	1.48e-05	7.68e-05	CcSEcCtD
Guanfacine—ADRA2B—Signaling by GPCR—IL2—hematologic cancer	4.4e-06	0.000165	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TERT—hematologic cancer	4.38e-06	0.000165	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—PIK3R1—hematologic cancer	4.34e-06	0.000163	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ARNTL—hematologic cancer	4.31e-06	0.000162	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PDGFB—hematologic cancer	4.28e-06	0.000161	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.27e-06	0.000161	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.22e-06	0.000158	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—JAK2—hematologic cancer	4.22e-06	0.000158	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—KRAS—hematologic cancer	4.2e-06	0.000158	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—MAP2K1—hematologic cancer	4.2e-06	0.000158	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CA9—hematologic cancer	4.19e-06	0.000157	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ACP5—hematologic cancer	4.19e-06	0.000157	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TSC2—hematologic cancer	4.18e-06	0.000157	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—GRB2—hematologic cancer	4.18e-06	0.000157	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—NQO1—hematologic cancer	4.17e-06	0.000157	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CD44—hematologic cancer	4.17e-06	0.000157	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—PIK3CD—hematologic cancer	4.17e-06	0.000157	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PDGFA—hematologic cancer	4.17e-06	0.000157	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—AKT1—hematologic cancer	4.16e-06	0.000156	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NCOR2—hematologic cancer	4.13e-06	0.000155	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—KITLG—hematologic cancer	4.11e-06	0.000154	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.09e-06	0.000153	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.04e-06	0.000152	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—FGFR3—hematologic cancer	4.02e-06	0.000151	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—STAT5A—hematologic cancer	4.02e-06	0.000151	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—PIK3CB—hematologic cancer	4e-06	0.00015	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—MTHFR—hematologic cancer	3.99e-06	0.00015	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MAPK14—hematologic cancer	3.98e-06	0.00015	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CDKN2B—hematologic cancer	3.98e-06	0.000149	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CYCS—hematologic cancer	3.95e-06	0.000148	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—PIK3R1—hematologic cancer	3.94e-06	0.000148	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—IDH1—hematologic cancer	3.94e-06	0.000148	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	3.92e-06	0.000147	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—ESR1—hematologic cancer	3.91e-06	0.000147	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTO1—hematologic cancer	3.89e-06	0.000146	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—TXN—hematologic cancer	3.89e-06	0.000146	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ABCC3—hematologic cancer	3.89e-06	0.000146	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—PIK3CA—hematologic cancer	3.86e-06	0.000145	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—FN1—hematologic cancer	3.86e-06	0.000145	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CD86—hematologic cancer	3.85e-06	0.000145	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—JAK2—hematologic cancer	3.83e-06	0.000144	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—BAD—hematologic cancer	3.81e-06	0.000143	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—NFKBIA—hematologic cancer	3.81e-06	0.000143	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—SPHK1—hematologic cancer	3.81e-06	0.000143	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—NQO1—hematologic cancer	3.81e-06	0.000143	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CD44—hematologic cancer	3.81e-06	0.000143	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HES1—hematologic cancer	3.8e-06	0.000143	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—NOTCH1—hematologic cancer	3.78e-06	0.000142	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—NCOR1—hematologic cancer	3.77e-06	0.000142	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—TP53—hematologic cancer	3.74e-06	0.00014	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—FGF1—hematologic cancer	3.73e-06	0.00014	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CSF2—hematologic cancer	3.73e-06	0.00014	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.73e-06	0.00014	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CD80—hematologic cancer	3.7e-06	0.000139	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PIK3CG—hematologic cancer	3.69e-06	0.000139	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—KIT—hematologic cancer	3.69e-06	0.000139	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—NRAS—hematologic cancer	3.69e-06	0.000139	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—FOXO1—hematologic cancer	3.68e-06	0.000138	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—IL2—hematologic cancer	3.68e-06	0.000138	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PDGFRB—hematologic cancer	3.67e-06	0.000138	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—UGT1A1—hematologic cancer	3.66e-06	0.000138	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—PIK3CB—hematologic cancer	3.64e-06	0.000137	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PTPN11—hematologic cancer	3.63e-06	0.000136	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PDGFRA—hematologic cancer	3.62e-06	0.000136	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—JAK1—hematologic cancer	3.6e-06	0.000135	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PRKCG—hematologic cancer	3.6e-06	0.000135	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CYCS—hematologic cancer	3.6e-06	0.000135	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	3.58e-06	0.000134	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—HRAS—hematologic cancer	3.57e-06	0.000134	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CRABP1—hematologic cancer	3.56e-06	0.000134	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	3.56e-06	0.000134	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—MAPK3—hematologic cancer	3.54e-06	0.000133	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.53e-06	0.000133	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CREB1—hematologic cancer	3.52e-06	0.000132	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTP1—hematologic cancer	3.48e-06	0.000131	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—BRAF—hematologic cancer	3.47e-06	0.00013	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ALOX5—hematologic cancer	3.47e-06	0.00013	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CCL2—hematologic cancer	3.44e-06	0.000129	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—IL6R—hematologic cancer	3.43e-06	0.000129	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CREBBP—hematologic cancer	3.43e-06	0.000129	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.37e-06	0.000126	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IL2RA—hematologic cancer	3.36e-06	0.000126	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NUP98—hematologic cancer	3.36e-06	0.000126	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PIK3CG—hematologic cancer	3.35e-06	0.000126	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—IL2—hematologic cancer	3.34e-06	0.000125	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TERT—hematologic cancer	3.33e-06	0.000125	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ABCB1—hematologic cancer	3.29e-06	0.000124	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MAP2K1—hematologic cancer	3.27e-06	0.000123	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ADCY7—hematologic cancer	3.26e-06	0.000123	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NCOA3—hematologic cancer	3.26e-06	0.000123	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PIK3CD—hematologic cancer	3.25e-06	0.000122	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	3.25e-06	0.000122	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NUP214—hematologic cancer	3.24e-06	0.000122	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.22e-06	0.000121	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—PIK3CA—hematologic cancer	3.22e-06	0.000121	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—NCOR1—hematologic cancer	3.2e-06	0.00012	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTM1—hematologic cancer	3.2e-06	0.00012	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—KRAS—hematologic cancer	3.18e-06	0.000119	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.17e-06	0.000119	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—MTR—hematologic cancer	3.17e-06	0.000119	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	3.17e-06	0.000119	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTP1—hematologic cancer	3.17e-06	0.000119	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—AKT1—hematologic cancer	3.15e-06	0.000118	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ENO2—hematologic cancer	3.11e-06	0.000117	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—FGF2—hematologic cancer	3.11e-06	0.000117	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CREBBP—hematologic cancer	3.11e-06	0.000117	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.07e-06	0.000115	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PIK3R1—hematologic cancer	3.07e-06	0.000115	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	3.05e-06	0.000115	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	3.02e-06	0.000114	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.02e-06	0.000113	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ABCB1—hematologic cancer	3e-06	0.000113	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—JAK2—hematologic cancer	2.98e-06	0.000112	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	2.97e-06	0.000111	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—SDC1—hematologic cancer	2.95e-06	0.000111	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PIK3CD—hematologic cancer	2.95e-06	0.000111	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—FN1—hematologic cancer	2.93e-06	0.00011	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—PIK3CA—hematologic cancer	2.92e-06	0.00011	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.92e-06	0.00011	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.92e-06	0.00011	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MDM2—hematologic cancer	2.91e-06	0.000109	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—ALB—hematologic cancer	2.91e-06	0.000109	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	2.89e-06	0.000109	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—BAD—hematologic cancer	2.89e-06	0.000109	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	2.87e-06	0.000108	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	2.83e-06	0.000106	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	2.83e-06	0.000106	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—MTHFR—hematologic cancer	2.83e-06	0.000106	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CD80—hematologic cancer	2.81e-06	0.000105	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	2.8e-06	0.000105	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—KIT—hematologic cancer	2.8e-06	0.000105	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	2.8e-06	0.000105	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PIK3R1—hematologic cancer	2.78e-06	0.000105	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	2.75e-06	0.000103	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	2.7e-06	0.000102	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	2.68e-06	0.000101	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	2.67e-06	0.0001	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	2.66e-06	9.98e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	2.63e-06	9.9e-05	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	2.63e-06	9.87e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	2.61e-06	9.8e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	2.6e-06	9.78e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	2.6e-06	9.78e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—IL2—hematologic cancer	2.6e-06	9.76e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	2.6e-06	9.76e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	2.59e-06	9.72e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—MTHFR—hematologic cancer	2.58e-06	9.68e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PIK3CB—hematologic cancer	2.57e-06	9.65e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	2.53e-06	9.52e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—JUN—hematologic cancer	2.53e-06	9.5e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CD44—hematologic cancer	2.51e-06	9.42e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NQO1—hematologic cancer	2.51e-06	9.42e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.49e-06	9.36e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	2.48e-06	9.32e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	2.46e-06	9.25e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	2.45e-06	9.21e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	2.45e-06	9.19e-05	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.44e-06	9.17e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	2.41e-06	9.06e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	2.39e-06	8.99e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	2.39e-06	8.96e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PIK3CG—hematologic cancer	2.37e-06	8.92e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CYCS—hematologic cancer	2.37e-06	8.92e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.36e-06	8.86e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	2.36e-06	8.86e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—EP300—hematologic cancer	2.33e-06	8.76e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	2.33e-06	8.74e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.27e-06	8.53e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—SRC—hematologic cancer	2.27e-06	8.52e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	2.26e-06	8.49e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PTEN—hematologic cancer	2.22e-06	8.34e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	2.22e-06	8.32e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	2.21e-06	8.3e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	2.21e-06	8.29e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CREBBP—hematologic cancer	2.2e-06	8.27e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	2.19e-06	8.22e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	2.18e-06	8.2e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PIK3CG—hematologic cancer	2.17e-06	8.13e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	2.15e-06	8.07e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	2.15e-06	8.07e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—EP300—hematologic cancer	2.12e-06	7.95e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.09e-06	7.86e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	2.09e-06	7.85e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PIK3CD—hematologic cancer	2.09e-06	7.84e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ALB—hematologic cancer	2.06e-06	7.74e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	2.05e-06	7.7e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	2.03e-06	7.63e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	2.03e-06	7.62e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	2.02e-06	7.57e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CREBBP—hematologic cancer	2.01e-06	7.54e-05	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.99e-06	7.49e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.98e-06	7.44e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.98e-06	7.42e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.97e-06	7.41e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.97e-06	7.4e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.96e-06	7.37e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.92e-06	7.22e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.92e-06	7.22e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.92e-06	7.22e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.92e-06	7.21e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.9e-06	7.15e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ALB—hematologic cancer	1.88e-06	7.06e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	1.88e-06	7.05e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.86e-06	6.99e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.86e-06	6.97e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.82e-06	6.83e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.82e-06	6.82e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.81e-06	6.8e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.8e-06	6.75e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.77e-06	6.65e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.73e-06	6.48e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.72e-06	6.46e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.7e-06	6.38e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.68e-06	6.3e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	1.67e-06	6.27e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.66e-06	6.23e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.66e-06	6.23e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.66e-06	6.22e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	1.6e-06	6e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	1.59e-06	5.96e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PTEN—hematologic cancer	1.57e-06	5.91e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	1.57e-06	5.88e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.54e-06	5.79e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.54e-06	5.78e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	1.53e-06	5.74e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—EP300—hematologic cancer	1.5e-06	5.63e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PTEN—hematologic cancer	1.43e-06	5.38e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.43e-06	5.36e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.43e-06	5.35e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	1.41e-06	5.29e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—EP300—hematologic cancer	1.37e-06	5.14e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.32e-06	4.97e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.31e-06	4.92e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—AKT1—hematologic cancer	1.28e-06	4.8e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.27e-06	4.76e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.26e-06	4.72e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ALB—hematologic cancer	1.24e-06	4.65e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.21e-06	4.55e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.19e-06	4.45e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.16e-06	4.35e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.11e-06	4.17e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.09e-06	4.11e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.07e-06	4.02e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.01e-06	3.8e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PTEN—hematologic cancer	9.46e-07	3.55e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—AKT1—hematologic cancer	9.06e-07	3.4e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—EP300—hematologic cancer	9.02e-07	3.39e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—AKT1—hematologic cancer	8.26e-07	3.1e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.67e-07	2.51e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—AKT1—hematologic cancer	5.45e-07	2.05e-05	CbGpPWpGaD
